ArticlePharmaceutics2022
Molecular Biocompatibility of a Silver Nanoparticle Complex with Graphene Oxide to Human Skin in a 3D Epidermis In Vitro Model.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- Advanced Immunomodulatory Biomaterials for Therapeutic Applications.Advanced healthcare materials · 2025Review
- The cytocompatibility of graphene oxide as a platform to enhance the effectiveness and safety of silver nanoparticles through in vitro studies.Environmental science and pollution research international · 2024Article
- Silver and Carbon Nanomaterials/Nanocomplexes as Safe and Effective ACE2-S Binding Blockers on Human Skin Cell Lines.Molecules (Basel, Switzerland) · 2024Article
- Antiviral Activity of Graphene Oxide-Silver Nanocomposites Against Murine Betacoronavirus.International journal of nanomedicine · 2024Article
- A Comprehensive Assessment of the Biocompatibility and Safety of Diamond Nanoparticles on Reconstructed Human Epidermis.Materials (Basel, Switzerland) · 2023Article
- Silver Nanoparticles and Graphene Oxide Complex as an Anti-Inflammatory Biocompatible Liquid Nano-Dressing for Skin Infected withJournal of inflammation research · 2023Article
- Graphene Oxide Decreases Pro-Inflammatory Proteins Production in Skeletal Muscle Cells Exposed to SARS-CoV-2 Spike Protein.Nanotechnology, science and applications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Silver nanoparticles (AgNP) can migrate to tissues and cells of the body, as well as to agglomerate, which reduces the effectiveness of their use for the antimicrobial protection of the skin. Graphene oxide (GO), with a super-thin flake structure, can be a carrier of AgNP that stabilizes their movement without inhibiting their antibacterial properties. Considering that the human skin is often the first contact with antimicrobial agent, the aim of the study was to assess whether the application of the complex of AgNP and GO is biocompatible with the skin model in in vitro studies. The conducted tests were performed in accordance with the criteria set in OECD TG439. AgNP-GO complex did not influence the genotoxicity and metabolism of the tissue. Furthermore, the complex reduced the pro-inflammatory properties of AgNP by reducing expression of IP-10 (interferon gamma-induced protein 10), IL-3 (interleukin 3), and IL-4 (interleukin 4) as well as MIP1β (macrophage inflammatory protein 1β) expressed in the GO group. Moreover, it showed a positive effect on the micro- and ultra-structure of the skin model. In conclusion, the synergistic effect of AgNP and GO as a complex can activate the process of epidermis renewal, which makes it suitable for use as a material for skin contact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.